New cancer Drug's hidden impact on cough medicine revealed
NCT ID NCT07241065
First seen Jun 26, 2026 · Last updated Jul 28, 2026 · Updated 3 times
Summary
This study looks at how a cancer drug called capivasertib changes the way the body processes dextromethorphan, a common cough suppressant. Researchers will give 42 healthy adults dextromethorphan alone and then with capivasertib to measure drug levels in the blood. The goal is to understand potential drug interactions for safer use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- capivasertib and dextromethorphan
- What this could lead to
- If successful, this study could help doctors understand how capivasertib interacts with other drugs, leading to safer dosing guidelines.
- What could go wrong
- This is an early-stage, small study in healthy people, not patients. Results may not predict effects in sick individuals or lead directly to new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Berlin, 14050, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates